Formulary Chapter 10: Musculoskeletal and joint diseases - Full Chapter
|
10.01.04 |
Gout and cytotoxic-induced hyperuricaemia |
|
|
10.01.04 |
Acute attacks of gout |
|
|
10.01.04 |
Long-term control of gout |
|
|
Allopurinol tabs
|
Formulary
|
Approved for all licensed indications
And the following off-label indication ( ):
In combination with thiopurines (i.e. azathioprine or mercaptopurine) in the treatment of Crohn’s Disease or Ulcerative Colitis where the patient has shown:

|
10.01.04 |
Hyperuricaemia associated with cytotoxic drugs |
|
|
Lesinurad tabs

|
Non Formulary
|
Not approved for use in SE London for treating chronic hyperuricaemia in people with gout as per NICE Technology Appraisal guidance (see link below) |
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|

|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |

|
Specialist initiation followed by maintenance prescribing in primary care |

|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |

|
Specialist and non-specialist initiation |

|
Not recommended for prescribing |
|
|